Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30259749 | 0.87 | DGAT1 (0.33) | DGAT1MAPT | |
| SCHEMBL27075020 | 0.86 | DGAT1 (0.34) | DGAT1MAPT | |
| SCHEMBL30968077 | 0.85 | DGAT1 (0.36) | DGAT1MAPT | |
| SCHEMBL19967487 | 0.84 | — | — | |
| SCHEMBL30379976 | 0.81 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL19949862 | 0.81 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL24122074 | 0.80 | DGAT1 (0.32) | DGAT1MAPT | |
| SCHEMBL24121750 | 0.80 | MAPT (0.31) | DGAT1MAPT | |
| SCHEMBL30304767 | 0.80 | MAPT (0.31) | DGAT1MAPT | |
| SCHEMBL19949143 | 0.79 | DGAT1 (0.33) | DGAT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115297-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL MED MOUNT SINAI (US) | 2026-04-30 | — | — | US | disclosed |
| US-12465648-B2 | Heterobifunctional compounds as degraders of HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-11-11 | — | — | US | disclosed |
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4524137-A2 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | Icahn School of Medicine at Mount Sinai (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-115768764-B | Parallel ring compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-3965824-B1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-118908962-A | Heterobifunctional compounds as degradation agents for HPK1 | 西奈山伊坎医学院 | 2024-11-08 | — | — | CN | disclosed |
| US-20240368127-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-02-01 | — | — | US | disclosed |
| EP-3856348-B1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS | INCYTE CORP (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2020227325-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-06-04 | — | — | US | disclosed |
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-06-04 | — | — | US | disclosed |
| WO-2020068729-A1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS | INCYTE CORPORATION (US) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020068729-A1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS | INCYTE CORPORATION (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20200095250-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-03-26 | — | — | US | disclosed |
| US-20200095250-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-03-26 | — | — | US | disclosed |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, MAPKAPK5 | DGAT1 4084/4885MAPT 3980/4885 |
| US-12465648-B2 | Heterobifunctional compounds as degraders of HPK1 | HIPK1, MCL1, HYPK | DGAT1 3042/4885MAPT 3290/4885 |
| US-20200095250-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | ALK, FGFR1, FGFR2 | DGAT1 3473/4885MAPT 4190/4885 |
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | ALK, FGFR1, FGFR2 | DGAT1 3473/4885MAPT 4190/4885 |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PDK2 | DGAT1 4059/4885MAPT 4245/4885 |
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | DGAT1 916/4885MAPT 2694/4885 |
| US-20260115297-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | TTK, ITK, CLK1 | DGAT1 4136/4885MAPT 3302/4885 |
| US-20240368127-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | DGAT1 916/4885MAPT 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.